According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
List view / Grid view
Steven G Jarvis (Head of Pharma & Biotech Segment Strategy - MilliporeSigma)
Assessing targets that are unable – or rather, extremely difficult – to reach pharmacologically, has prevented researchers from achieving desired clinical successes, most notably in the realm of cancer research. However, many advances are being made to shedlight on these difficult yet desirable target areas.
The pursuit of improved R&D productivity rates coupled with decreased cycle times has dominated pharmaceutical discourse in recent years.
Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.
Assay robustness tends to be the favoured descriptor when a particular assay can cope with minute changes in the sample, equipment, or operator. The more robust an assay, the more predictive data it ultimately yields. The industry’s greatest challenge for assay development has always been using those robust assays to…